Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis

$600,660U54FY2014CANIH

Methodist Hospital Research Institute, Houston TX

Investigators

Linked publications & trials

Paper 37714187 Paper 37593365 Paper 37124705 Paper 35863672 Paper 35643254 Paper 35417569 Paper 34980020 Paper 33688489 Paper 32298994 Paper 32189815 Paper 32061993 Paper 30790060 Paper 30697890 Paper 30501557 Paper 30457357 Paper 30082477 Paper 29921732 Paper 29621664 Paper 29602802 Paper 29537266 Paper 29464004 Paper 29386574 Paper 29370450 Paper 29182964 Paper 29177085 Paper 29110053 Paper 29062065 Paper 28933296 Paper 28791195 Paper 28719856 Paper 28687352 Paper 28670454 Paper 28640590 Paper 28611425 Paper 28527736 Paper 28179157 Paper 28104923 Paper 27826372 Paper 27722511 Paper 27713932 Paper 27703233 Paper 27690153 Paper 27627810 Paper 27546164 Paper 27445473 Paper 27429662 Paper 27394167 Paper 27301181 Paper 27257995 Paper 27213956 Paper 27123698 Paper 27091777 Paper 27058005 Paper 26977286 Paper 26974511 Paper 26890862 Paper 26839407 Paper 26830354 Paper 26820961 Paper 26818212 Paper 26806807 Paper 26761780 Paper 26749465 Paper 26744528 Paper 26660469 Paper 26653875 Paper 26601723 Paper 26601238 Paper 26502889 Paper 26424126 Paper 26420723 Paper 26409121 Paper 26404901 Paper 26348965 Paper 26314276 Paper 26308617 Paper 26264836 Paper 26257819 Paper 26204522 Paper 26167143 Paper 26165830 Paper 26139126 Paper 26000054 Paper 25937283 Paper 25901526 Paper 25897337 Paper 25878124 Paper 25835222 Paper 25822693 Paper 25788574 Paper 25788424 Paper 25726964 Paper 25721343 Paper 25666164 Paper 25595279 Paper 25588379 Paper 25570493 Paper 25559154 Paper 25496453 Paper 25485265

Abstract

Liver metastasis is a common occurrence during the course of gastrointestinal disease. It has been found in 30-70% of patients who are dying of various malignancies including colorectal, breast, lung, and pancreas cancer. Surgery is a common therapy for liver metastasis; however, 5-year survival rates range from 25-40%, indicating the need to develop novel therapies. A part of developing novel therapies is the necessity to understand the development of liver metastasis. Kupffer cells (KC), the phagocytic cells of the liver, comprise approximately 10% of all hepatic cells. The role of KC in liver metastasis is not clearly understood; more specifically, it is not understood whether KC plays a defensive role against liver metastasis or enhances its angiogenesis. A better understanding of liver metastasis development and the role of KC is necessary to develop novel treatments for liver metastases. Another challenge in the treatment of cancers, including liver metastases, is the distribution of imaging and therapeutic agents to intended targets. Systemically administered drug molecules or contrast agents only reach their desired targets one part per 10,000-100,000. The overall goal of this project is to develop a broader understanding of physical barriers and biological factors involved in the progression of liver metastasis in orthotopic models of colorectal cancer and to design novel biocompatible delivery carriers able to overcome or take an advantage of these barriers with favorable pharmacokinetics and tissue distribution for highly efficient delivery of novel therapeutic agents and imaging agents. This project aims to image liver metastasis development and localization of KC in order to design an in silico model for administration of therapies and use a physical modeling process to optimize the properties of nanocarriers. Additionally, this project aims to refine, design, and evaluate biocompatibility of nanovectors for delivery of therapeutic and contrast agents for treatment of liver metastases, and to determine therapeutic and imaging efficacy of co-delivery of gold nanoparticles and cytotoxic agents from rationally designed targeted multi-stage nanovectors in in-vivo models of liver metastases.

View original record on NIH RePORTER →